References
1. Benjamin EJ, Muntner P, Alonso A, et al. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association.Circulation. 2019;139(10):e56-e528.
2. Staerk L, Sherer JA, Ko D, Benjamin EJ, Helm RH. Atrial Fibrillation: Epidemiology, Pathophysiology, and Clinical Outcomes. Circ Res.2017;120(9):1501-1517.
3. Guo Y, Tian Y, Wang H, Si Q, Wang Y, Lip GYH. Prevalence, incidence, and lifetime risk of atrial fibrillation in China: new insights into the global burden of atrial fibrillation. Chest. 2015;147(1):109-119.
4. Dewland TA, Olgin JE, Vittinghoff E, Marcus GM. Incident atrial fibrillation among Asians, Hispanics, blacks, and whites.Circulation. 2013;128(23):2470-2477.
5. O’Neal WT, Tanner RM, Efird JT, et al. Atrial fibrillation and incident end-stage renal disease: The REasons for Geographic And Racial Differences in Stroke (REGARDS) study. International journal of cardiology. 2015;185:219-223.
6. Kalantarian S, Stern TA, Mansour M, Ruskin JN. Cognitive impairment associated with atrial fibrillation: a meta-analysis. Annals of internal medicine. 2013;158(5 Pt 1):338-346.
7. Bansal N, Fan D, Hsu CY, Ordonez JD, Marcus GM, Go AS. Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. Circulation. 2013;127(5):569-574.
8. Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation.2003;107(23):2920-2925.
9. Wilber DJ, Pappone C, Neuzil P, et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial.Jama. 2010;303(4):333-340.
10. Packer DL, Mark DB, Robb RA, et al. Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. Jama. 2019;321(13):1261-1274.
11. Mont L, Bisbal F, Hernandez-Madrid A, et al. Catheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: a multicentre, randomized, controlled trial (SARA study). European heart journal. 2014;35(8):501-507.
12. Marrouche NF, Brachmann J, Andresen D, et al. Catheter Ablation for Atrial Fibrillation with Heart Failure. The New England journal of medicine. 2018;378(5):417-427.
13. Pappone C, Augello G, Sala S, et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study. Journal of the American College of Cardiology. 2006;48(11):2340-2347.
14. Packer DL, Kowal RC, Wheelan KR, et al. Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial. Journal of the American College of Cardiology. 2013;61(16):1713-1723.
15. Jais P, Cauchemez B, Macle L, et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study.Circulation. 2008;118(24):2498-2505.
16. Calkins H, Reynolds MR, Spector P, et al. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. Circulation Arrhythmia and electrophysiology. 2009;2(4):349-361.
17. Poole JE, Bahnson TD, Monahan KH, et al. Recurrence of Atrial Fibrillation After Catheter Ablation or Antiarrhythmic Drug Therapy in the CABANA Trial. Journal of the American College of Cardiology.2020;75(25):3105-3118.
18. Jin MN, Kim TH, Kang KW, et al. Atrial Fibrillation Catheter Ablation Improves 1-Year Follow-Up Cognitive Function, Especially in Patients With Impaired Cognitive Function. Circulation Arrhythmia and electrophysiology. 2019;12(7):e007197.
19. Takahashi Y, Takahashi A, Kuwahara T, et al. Renal function after catheter ablation of atrial fibrillation. Circulation.2011;124(22):2380-2387.
20. Fichtner S, Deisenhofer I, Kindsmuller S, et al. Prospective assessment of short- and long-term quality of life after ablation for atrial fibrillation. Journal of cardiovascular electrophysiology.2012;23(2):121-127.
21. Wang Q, Zhang XD, Liu X, Yang YQ. Renal function after repeat catheter ablation for long-standing persistent atrial fibrillation : Low CHA2DS2-VASc score and sinus rhythm predict improved renal function.Herz. 2016;41(4):331-341.
22. Park JW, Yang PS, Bae HJ, et al. Five-Year Change in the Renal Function After Catheter Ablation of Atrial Fibrillation. Journal of the American Heart Association. 2019;8(17):e013204.
23. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate.
24. Yang B, Jiang C, Lin Y, et al. STABLE-SR (Electrophysiological Substrate Ablation in the Left Atrium During Sinus Rhythm) for the Treatment of Nonparoxysmal Atrial Fibrillation: A Prospective, Multicenter Randomized Clinical Trial. Circulation Arrhythmia and electrophysiology. 2017;10(11).
25. National Kidney F. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1-266.
26. Chapter 2: Definition, identification, and prediction of CKD progression. Kidney Int Suppl (2011). 2013;3(1):63-72.
27. Turin TC, James M, Ravani P, et al. Proteinuria and rate of change in kidney function in a community-based population. Journal of the American Society of Nephrology : JASN. 2013;24(10):1661-1667.
28. Kidney Disease Outcomes Quality I. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(5 Suppl 1):S1-290.
29. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). European heart journal. 2020.
30. Pandey A, Kim S, Moore C, et al. Predictors and Prognostic Implications of Incident Heart Failure in Patients With Prevalent Atrial Fibrillation. JACC Heart Fail. 2017;5(1):44-52.
31. Ganesan AN, Chew DP, Hartshorne T, et al. The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis. European heart journal. 2016;37(20):1591-1602.
32. Link MS, Giugliano RP, Ruff CT, et al. Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48). Circulation Arrhythmia and electrophysiology. 2017;10(1).
33. Cosedis Nielsen J, Johannessen A, Raatikainen P, et al. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. The New England journal of medicine.2012;367(17):1587-1595.
34. Pallisgaard JL, Gislason GH, Hansen J, et al. Temporal trends in atrial fibrillation recurrence rates after ablation between 2005 and 2014: a nationwide Danish cohort study. European heart journal.2018;39(6):442-449.
35. Andrade JG, Champagne J, Dubuc M, et al. Cryoballoon or Radiofrequency Ablation for Atrial Fibrillation Assessed by Continuous Monitoring: A Randomized Clinical Trial. Circulation.2019;140(22):1779-1788.
Table 1. Clinical characteristics at baseline during the initial admission before RFCA.